DV
Dividend Vision

TBPH — Theravance Biopharma, Inc.

Theravance Biopharma, Inc. (TBPH)

Total return is -26.1% over the past 12.2 years, 433.4 points behind SPY at 407.3%. Its deepest 1-year drawdown was 34.6%.

Theravance Biopharma, Inc. is an individual equity stock in the healthcare sector, a biopharmaceutical company focused on developing and commercializing medicines, with a notable royalty interest in the respiratory franchise it helped create. The company does not pay a fixed regular dividend, instead returning capital opportunistically through buybacks and periodic distributions tied to its royalty cash flows. This small-cap security suits investors seeking healthcare exposure with potential capital-return optionality rather than a predictable dividend stream.

TBPH key facts

Asset type
Stock
Asset class
Equity
Distribution frequency
None
Last close
$16.97
Market cap
$881,061,184
Average volume
405435.0
Beta
0.246
Payout ratio
0.0
P/E ratio
16.3173
Forward P/E
7.8989
EPS
$1.04